Botanix Pharmaceuticals

BOT.AX

Perth, Australia· Est. 2007

botanixpharma.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

BOT.AX · Stock Price

AUD 0.03-0.02 (-42.55%)

Market Cap: $53.2M

Historical price data

Market Cap: $53.2MPipeline: 10 drugs (3 Phase 3)Founded: 2007Employees: Lean team (likely 20-50)HQ: Perth, Australia

Sector Ranking#96 in Drug Delivery & Formulation #286 in Small Molecule Drugs

Overview

Botanix Pharmaceuticals is a clinical-stage biotech focused on developing and commercializing novel dermatology and antimicrobial therapeutics. Its core achievement is the FDA approval and US launch of Sofdra™, a first-in-class topical anticholinergic for excessive underarm sweating, which is also approved in Japan and South Korea. The company's strategy leverages a dual-technology platform—Permetrex™ for enhanced skin delivery and synthetic CBD for its anti-inflammatory and antimicrobial properties—to address large, underserved markets. With a lean, US-focused commercial operation and an experienced leadership team, Botanix aims to transform its pipeline into a portfolio of high-value dermatology products.

DermatologyAnti-infectives

Technology Platform

Proprietary Permetrex™ transdermal delivery technology combined with deep expertise in the pharmaceutical application of synthetic cannabidiol (CBD) for its anti-inflammatory, antimicrobial, and sebostatic properties.

Pipeline

10 drugs in pipeline3 in Phase 3

Drug	Indication	Stage
Sofpironium Bromide, 15% + Vehicle	Axillary Hyperhidrosis	Phase 3
Sofpironium Bromide Gel, 15% + Vehicle	Axillary Hyperhidrosis	Phase 3
Sofpironium Bromide Gel, 5% + Sofpironium Bromide Gel, 15%	Primary Axillary Hyperhidrosis	Phase 3
BBI-4000 gel, 5% + BBI-4000 gel, 10% + BBI-4000 gel, 15% + V...	Hyperhidrosis	Phase 2
BBI-4000 Gel, 5% + BBI-4000 Gel, 10% + BBI-4000 Gel, 15% + V...	Hyperhidrosis	Phase 2

Funding History

Total raised:$30.5M

Placement$15MUndisclosedJun 15, 2022

Placement$10.3MUndisclosedDec 15, 2020

IPO$5.2MUndisclosedJul 1, 2015

Opportunities

Sofdra™ addresses a >$1B US hyperhidrosis market with a first-in-class topical option.

The synthetic CBD platform offers a novel mechanism to target large, underserved dermatology markets like acne and rosacea, and a potential breakthrough in combating antimicrobial resistance (MRSA).

Risk Factors

Commercial execution risk for the Sofdra™ launch is paramount.

The clinical pipeline carries development and regulatory risk, and the company may require further dilutive capital raises to fund operations and growth.

Competitive Landscape

In hyperhidrosis, competes with Botox, miraDry, and Qbrexza. In acne/rosacea, faces crowded markets with generics and established branded therapies. Differentiation hinges on novel CBD mechanism and enhanced topical delivery via Permetrex™.